OBJECTIVE： To observe clinical efficacy and safety of montelukast combined with moxifloxacin in the treatment of cough of acute bacterial bronchitis. METHODS： A total of 139 cases of cough of acute bacterial bronchitis selected from outpatient department of Ningbo Yinzhou District Qianhu Hospital during Jan.-Dec. 2016 were divided into control group （69 cases） and observation group （70 cases） according to random number table. Control group was given Moxifloxacin hydrochloride tablets 0.4 g， po， qd； observation group was additionally given Montelukast sodium tablets 10 mg， po， once every night， on the basis of control group. Both groups were treated for 6 d. Cough symptom scores， peripheral blood WBC and CRP contents were compared between 2 groups before and after treatment. Clinical efficacies， the occurrence of ADR and clinical outcome were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in cough symptom scores， peripheral blood WBC or CRP contents between 2 groups （P＞0.05）. Compared to before treatment， cough symptom scores， peripheral blood WBC and CRP contents of 2 groups were decreased significantly after treatment， and the cough symptom score of observation group after 3 d of treatment was significantly lower than that of control group at the same time， with statistical significance （P＜0.05）. There was no statistical significance in above indexes between 2 groups after 6 d of treatment （P＞0.05）. Cure rate of observation group was 64.29％， which was significantly higher than 44.93％ of control group， with statistical significance （P＜0.05）. Response rates of observation group and control group were 97.14％ and 97.10％， there was no statistical significance （P＞0.05）. No ADR was found in 2 groups during treatment， and good clinical outcome was obtained. CONCLUSIONS： Montlukast combined with moxifloxacin not only relieve cough symptom and inflammation， but also improve cure rate significantly with good safety.